Curis Inc

CUS0

Company Profile

  • Business description

    Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

  • Contact

    128 Spring Street
    Building C - Suite 500
    LexingtonMA02421
    USA

    T: +1 617 503-6500

    E: [email protected]

    https://www.curis.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2024

    Employees

    49

Stocks News & Analysis

stocks

The surge in price of ASX listed share price is unwarranted

Good news as a proposed merger is approved but investors may be too optimistic. 
stocks

11 ASX dividend stocks for the next decade

What are the best stocks to own that can pay regular dividends and beat indices on a total return basis in the long-term? Here is our list of 11 ASX-listed companies that could help investors achieve these goals.
stocks

10 defensive ASX stocks to own in an expensive market

These shares may protect an investor in a volatile market. 

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,552.6071.000.84%
CAC 407,338.6786.93-1.17%
DAX 4019,215.48147.04-0.76%
Dow JONES (US)43,988.99259.650.59%
FTSE 1008,072.3968.35-0.84%
HKSE20,728.19225.15-1.07%
NASDAQ19,286.7817.320.09%
Nikkei 22539,500.37118.960.30%
NZX 50 Index12,770.33188.951.50%
S&P 5005,995.5422.440.38%
S&P/ASX 2008,295.1068.800.84%
SSE Composite Index3,452.3018.36-0.53%

Market Movers